Nov 17 (Reuters) - Lumexa reported a narrower loss for

the first nine months of 2025, the Welsh, Carson, Anderson &

Stowe-backed medical imaging firm revealed in its U.S. initial

public offering paperwork on Monday, aiming to tap a gradually

reopening new listings window.

IPO activity in the U.S had recovered from tariff shocks to

have its busiest autumn in four years, before the longest

partisan gridlock in Washington curbed the SEC's ability to

review filings.

Now, the window for first-time share sales during the

year-end continues to narrow, analysts have said, as the holiday

season curbs flexibility of listing plans.

Private equity sponsors are sitting on a record backlog of

companies primed to go public, as soaring equity markets and

falling interest rates set the stage for a long-awaited IPO

market recovery.

Earlier on Monday, York Space Systems filed to list its

shares on the New York Stock Exchange.

Lumexa runs 184 outpatient imaging centers in 13 states,

delivering advanced and affordable diagnostic imaging services

such as MRI and CT.

Its listing plans come at a time when AI-driven tools and

analytics are promising to improve diagnostic accuracy, lower

healthcare costs and expand patient access to high-quality

imaging tools.

"The rapid development of AI tools could also render

obsolete certain technologies or tools we currently use," Lumexa

said in its prospectus.

Following the closing of its offering, Lumexa also aims to

appoint former IBM and Microsoft executives to its board of

directors.

The company reported a loss of $18.4 million on $755.3

million of revenue for the nine months ended September 30,

compared with loss of $69 million on revenue of $700.8 million a

year earlier.

Barclays, J.P. Morgan, and Jefferies are the lead

underwriters on the offering.

The company aims to list its shares on the Nasdaq under the

symbol "LMRI".